- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Retail pharmacy sales on the rise
The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.
The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.
Driven by the success of Imitrex, Flonase, Epivir and Serevent, Glaxo Wellcome was responsible for the largest portion (6.7%) of retail pharmacy sales. Merck added the second largest share (6.5%) with Aocor, Fosamax, Cozaar and Hyzaar. Pfizer contributed the third largest sales (6.2%) with strong performances by Norvasc, Cardura, Zithromax and Zyrtec.
American Home Products and Bristol-Myers Squibb rounded out the top five in second-quarter sales with 6% and 5.7%, respectively.
Four of the top 10 corporations increased their U.S. retail pharmacy dollars by more than 20%: Eli Lilly and SmithKline Beecham raised their revenues by 21%; Bristol-Myers Squibb improved its stance by 24%; and Schering-Plough boosted its sales by 32%. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
